China Resources Double Crane passes GMP inspection

China Resources Double Crane Pharmaceutical has received notification from the Beijing Drug Administration confirming GMP compliance for its new integrated solid preparation production line in the comprehensive manufacturing workshop and its rinsing agent Q-line in the soft bag infusion workshop. The inspection, conducted in April 2025, covers the production of Mercaptopurine Tablets (II) and Sodium Chloride Injection. The company invested CNY 1,033.10 million in these production lines. The announcement also highlights the market position of these drugs, noting that the global sales of Mercaptopurine Tablets were USD 4,165.65 million in 2023. The company states the GMP compliance will maintain stable product quality, and further ensure production capacity to meet market demand. The company does not expect this to significantly impact on earnings.